FOXO3 and urinary bladder carcinoma: Indeed, our in vitro (Figure 2) and in vivo (Figure 5) studies indicated a strong increase of FOXO3a in the CAP-treated bladder cancer cells, suggesting that the induction of cell cycle arrest and ROS production triggered by CAP could be via FOXO3a-mediated pathways.